BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00949650
First received: July 29, 2009
Last updated: December 5, 2013
Last verified: October 2013
  Purpose

This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma
Drug: Pemetrexed
Drug: BIBW 2992
Drug: Cisplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Progression-free Survival (PFS) Time [ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks or until death ] [ Designated as safety issue: No ]
    PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates. Only data collected until the primary endpoint analysis cut-off date (09 February 2012) were considered.


Secondary Outcome Measures:
  • Percentage of Patients With Objective Response (OR) [ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks ] [ Designated as safety issue: No ]
    OR is defined as complete response (CR) and partial response (PR). Assessed by central independent review according to RECIST 1.1. Only data collected until the primary endpoint analysis cut-off date (09 February 2012) were considered.

  • Percentage of Participants With Disease Control (DC) [ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks ] [ Designated as safety issue: No ]
    DC is defined as a patient with OR or stable disease (SD). Assessed by central independent review according to the RECIST 1.1. Only data collected until the primary endpoint analysis cut-off date were considered.

  • Overall Survival (OS) Time [ Time Frame: From randomisation to primary endpoint analysis cut-off date. ] [ Designated as safety issue: No ]
    OS is defined as time from randomisation to death.

  • Tumour Shrinkage [ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks ] [ Designated as safety issue: No ]
    Tumour shrinkage is calculated as the minimum sum of diameters (SoD) of target lesions from all post-baseline tumour assessments, as read by the central independent review. The mean of these minimum values are presented after adjusting for baseline SoD, EGFR mutation group and race.

  • Change From Baseline in Body Weight [ Time Frame: Baseline and throughout the trial until progression (every 3 weeks), up to 28 month ] [ Designated as safety issue: No ]
    Because the PFS was longer for patients in the afatinib arm than for patients in the chemotherapy arm, the period of data collection for ECOG status and body weight continued for a longer time in the afatinib arm.

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) [ Time Frame: Throughout the trial until progression (every 3 weeks), up to 28 month ] [ Designated as safety issue: No ]
    ECOG PS measured on 6 point scale to assess participants performance status. 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work; 2=Ambulatory (>50 percent of waking hours), capable of all selfcare, unable to carry out any work activities; 3=Capable of only limited self care, confined to bed or chair more then 50 percent of waking hours; 4=Completely disabled, cannot carry on any selfcare, totally confined to bed or chair; 5=Dead.

  • Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing [ Time Frame: Throughout the trial until progression (every 3 weeks) ] [ Designated as safety issue: No ]
    HRQOL was measured by European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire C30 (QLQ-C30) and its lung cancerspecific module LC13 (QLQ-LC13). Analysis for cough is based on QLQ-LC13 question 1. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.

  • HRQOL: Time to Deterioration in Dyspnoea [ Time Frame: Throughout the trial until progression (every 3 weeks) ] [ Designated as safety issue: No ]
    HRQOL was measured by EORTC QLQ-C30 and its lung cancerspecific module QLQ-LC13. Analysis for dyspnoea is based on composite of QLQ-LC13 questions 3-5. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.

  • HRQOL: Time to Deterioration in Pain [ Time Frame: Throughout the trial until progression (every 3 weeks) ] [ Designated as safety issue: No ]
    HRQOL was measured by EORTC QLQ-C30 and its lung cancerspecific module QLQ-LC13. Analysis for pain is based on composite of QLQ-C30 questions 9 and 19. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.

  • Trough Plasma Concentrations of Afatinib at Day 22 [ Time Frame: Day 22 ] [ Designated as safety issue: No ]
    Trough plasma concentrations of afatinib at day 22 (course 2, visit 1) after multiple daily dosing of 40mg afatinib and after dose escalation to 50 mg or dose reduction to 30mg or 20mg.

  • Trough Plasma Concentrations of Afatinib at Day 29 [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
    Trough plasma concentrations of afatinib at day 29 (course 2, visit 2) after multiple daily dosing of 40mg afatinib and after dose escalation to 50 mg or dose reduction to 30mg or 20mg.

  • Trough Plasma Concentrations of Afatinib at Day 43 [ Time Frame: Day 43 ] [ Designated as safety issue: No ]
    Trough plasma concentrations of afatinib at day 43 (course 3, visit 1) after multiple daily dosing of 40mg afatinib and after dose escalation to 50 mg or dose reduction to 30mg or 20mg.


Enrollment: 345
Study Start Date: August 2009
Estimated Study Completion Date: December 2013
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBW 2992
BIBW 2992 tablet once daily until progression
Drug: BIBW 2992
BIBW 2992 once daily until progression
Active Comparator: Cisplatin/Pemetrexed
Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
Drug: Pemetrexed
Pemetrexed IV given once every 3 weeks for up to 6 cycles
Drug: Cisplatin
Cisplatin IV given once every 3 weeks for up to 6 cycles

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
  • Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material.
  • Measurable disease according to RECIST 1.1.
  • Eastern Cooperative Oncology Group score of 0 or 1.
  • Age >/= 18 years.
  • Life expectancy of at least three months.
  • Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion criteria:

  • Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation.
  • Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies.
  • Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.
  • Active brain metastases
  • Any other current malignancy or malignancy diagnosed within the past five years
  • Known pre-existing interstitial lung disease.
  • Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom.
  • History or presence of clinically relevant cardiovascular abnormalities.
  • Any other concomitant serious illness or organ system dysfunction.
  • Adequate absolute neutrophil count and platelet count
  • Adequate liver and kidney function
  • Active hepatitis B infection, active hepatitis C infection or known HIV carrier.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00949650

  Hide Study Locations
Locations
United States, Arkansas
1200.32.2605 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas, United States
United States, California
1200.32.2617 Boehringer Ingelheim Investigational Site
Montebello, California, United States
United States, Florida
1200.32.2616 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
United States, Louisiana
1200.32.2606 Boehringer Ingelheim Investigational Site
Marrero, Louisiana, United States
United States, New York
1200.32.2603 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
United States, Pennsylvania
1200.32.2608 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
United States, Texas
1200.32.2609 Boehringer Ingelheim Investigational Site
Corpus Christie, Texas, United States
Argentina
1200.32.2111 Boehringer Ingelheim Investigational Site
Bahía Blanca, Argentina
1200.32.2101 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2107 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2106 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2115 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2102 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2112 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1200.32.2110 Boehringer Ingelheim Investigational Site
Rosario, Argentina
Australia, New South Wales
1200.32.2711 Boehringer Ingelheim Investigational Site
Camperdown, New South Wales, Australia
1200.32.2701 Boehringer Ingelheim Investigational Site
St Leonards, New South Wales, Australia
1200.32.2705 Boehringer Ingelheim Investigational Site
Waratah, New South Wales, Australia
Australia, Queensland
1200.32.2703 Boehringer Ingelheim Investigational Site
Chermside, Queensland, Australia
Australia, South Australia
1200.32.2704 Boehringer Ingelheim Investigational Site
Bedford Park, South Australia, Australia
1200.32.2709 Boehringer Ingelheim Investigational Site
Toorak Gardens, South Australia, Australia
Australia, Victoria
1200.32.2702 Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
1200.32.2706 Boehringer Ingelheim Investigational Site
Fitzroy, Victoria, Australia
Australia, Western Australia
1200.32.2707 Boehringer Ingelheim Investigational Site
Perth, Western Australia, Australia
Austria
1200.32.5103 Boehringer Ingelheim Investigational Site
Linz, Austria
1200.32.5104 Boehringer Ingelheim Investigational Site
Wels, Austria
1200.32.5101 Boehringer Ingelheim Investigational Site
Wien, Austria
Belgium
1200.32.4103 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
1200.32.4105 Boehringer Ingelheim Investigational Site
Gent, Belgium
1200.32.4101 Boehringer Ingelheim Investigational Site
Jette, Belgium
1200.32.4107 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1200.32.4102 Boehringer Ingelheim Investigational Site
Liège, Belgium
Brazil
1200.32.2204 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1200.32.2207 Boehringer Ingelheim Investigational Site
Cachoeiro de Itapemirim, Brazil
1200.32.2208 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1200.32.2202 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1200.32.2201 Boehringer Ingelheim Investigational Site
Sao Paulo, Brazil
Canada, Alberta
1200.32.2905 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1200.32.2902 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
Canada, Quebec
1200.32.2904 Boehringer Ingelheim Investigational Site
Greenfield Park, Quebec, Canada
1200.32.2903 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1200.32.2901 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Chile
1200.32.2301 Boehringer Ingelheim Investigational Site
Los Condes, Chile
1200.32.2303 Boehringer Ingelheim Investigational Site
Reñaca, Chile
1200.32.2302 Boehringer Ingelheim Investigational Site
Temuco, Chile
France
1200.32.4211A Boehringer Ingelheim Investigational Site
Angers, France
1200.32.4204A Boehringer Ingelheim Investigational Site
Caen Cedex 5, France
1200.32.4202A Boehringer Ingelheim Investigational Site
La Tronche, France
1200.32.4201A Boehringer Ingelheim Investigational Site
Lyon Cedex 4, France
1200.32.4210A Boehringer Ingelheim Investigational Site
Paris Cedex 05, France
1200.32.4207A Boehringer Ingelheim Investigational Site
Saint Herblain, France
1200.32.4215A Boehringer Ingelheim Investigational Site
Saint-Pierre Cedex - La Réunion, France
1200.32.4212A Boehringer Ingelheim Investigational Site
Toulon, France
1200.32.4206A Boehringer Ingelheim Investigational Site
Villefranche Sur Saône, France
Germany
1200.32.4304 Boehringer Ingelheim Investigational Site
Berlin, Germany
1200.32.4305 Boehringer Ingelheim Investigational Site
Essen, Germany
1200.32.4301 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1200.32.4306 Boehringer Ingelheim Investigational Site
Hannover, Germany
1200.32.4309 Boehringer Ingelheim Investigational Site
Hemer, Germany
1200.32.4310 Boehringer Ingelheim Investigational Site
Mainz, Germany
1200.32.4311 Boehringer Ingelheim Investigational Site
Münster, Germany
1200.32.4308 Boehringer Ingelheim Investigational Site
Oldenburg, Germany
Hong Kong
1200.32.3102 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1200.32.3101 Boehringer Ingelheim Investigational Site
Shatin, Hong Kong
Hungary
1200.32.5302 Boehringer Ingelheim Investigational Site
Szekesfehervar, Hungary
1200.32.5301 Boehringer Ingelheim Investigational Site
Szombathely, Hungary
1200.32.5304 Boehringer Ingelheim Investigational Site
Zalaegerszeg, Hungary
Ireland
1200.32.4401 Boehringer Ingelheim Investigational Site
Dublin 8, Ireland
Italy
1200.32.4503 Boehringer Ingelheim Investigational Site
Arezzo, Italy
1200.32.4502 Boehringer Ingelheim Investigational Site
Prato, Italy
1200.32.4504 Boehringer Ingelheim Investigational Site
Roma, Italy
1200.32.4501 Boehringer Ingelheim Investigational Site
Sant'Andrea delle Fratte (PG), Italy
Japan
1200.32.3207 Boehringer Ingelheim Investigational Site
Fukuoka, Fukuoka, Japan
1200.32.3211 Boehringer Ingelheim Investigational Site
Kanazawa, Ishikawa, Japan
1200.32.3203 Boehringer Ingelheim Investigational Site
Kashiwa, Chiba, Japan
1200.32.3219 Boehringer Ingelheim Investigational Site
Kobe, Hyogo, Japan
1200.32.3214 Boehringer Ingelheim Investigational Site
Kurashiki,Okayama, Japan
1200.32.3220 Boehringer Ingelheim Investigational Site
Matsuyama, Ehime, Japan
1200.32.3206 Boehringer Ingelheim Investigational Site
Miyakojima-ku, Osaka, Japan
1200.32.3204 Boehringer Ingelheim Investigational Site
Nagoya, Aichi, Japan
1200.32.3217 Boehringer Ingelheim Investigational Site
Nagoya, Aichi, Japan
1200.32.3216 Boehringer Ingelheim Investigational Site
Niigata, Niigata, Japan
1200.32.3209 Boehringer Ingelheim Investigational Site
Okayama, Okayama, Japan
1200.32.3205 Boehringer Ingelheim Investigational Site
Osaka-Sayama, Osaka, Japan
1200.32.3218 Boehringer Ingelheim Investigational Site
Sakai, Osaka, Japan
1200.32.3215 Boehringer Ingelheim Investigational Site
Sapporo, Hokkaido, Japan
1200.32.3202 Boehringer Ingelheim Investigational Site
Sunto-gun, Shizuoka, Japan
1200.32.3221 Boehringer Ingelheim Investigational Site
Yokohama, Kanagawa, Japan
Korea, Republic of
1200.32.3304 Boehringer Ingelheim Investigational Site
Cheongju, Korea, Republic of
1200.32.3302 Boehringer Ingelheim Investigational Site
Hwasun, Korea, Republic of
1200.32.3303 Boehringer Ingelheim Investigational Site
Seongnam, Korea, Republic of
1200.32.3301 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.32.3305 Boehringer Ingelheim Investigational Site
Ulsan, Korea, Republic of
Malaysia
1200.32.3402 Boehringer Ingelheim Investigational Site
Palau Pinang, Malaysia
1200.32.3403 Boehringer Ingelheim Investigational Site
Wilayah Persekutuan, Malaysia
1200.32.3401 Boehringer Ingelheim Investigational Site
Wilayah Persekutuan, Malaysia
Peru
1200.32.2501 Boehringer Ingelheim Investigational Site
La Victoria, Peru
1200.32.2505 Boehringer Ingelheim Investigational Site
San Isidro, Peru
1200.32.2503 Boehringer Ingelheim Investigational Site
Surquillo, Peru
Philippines
1200.32.3501 Boehringer Ingelheim Investigational Site
Cebu City, Philippines
1200.32.3503 Boehringer Ingelheim Investigational Site
Makati City, Philippines
1200.32.3502 Boehringer Ingelheim Investigational Site
Quezon, Philippines
Romania
1200.32.5402 Boehringer Ingelheim Investigational Site
Cluj Napoca, Romania
1200.32.5401 Boehringer Ingelheim Investigational Site
Craiova, Romania
Russian Federation
1200.32.5506 Boehringer Ingelheim Investigational Site
Kazan, Russian Federation
1200.32.5505 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1200.32.5507 Boehringer Ingelheim Investigational Site
Obninsk, Russian Federation
1200.32.5501 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1200.32.5504 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1200.32.5503 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Taiwan
1200.32.3607 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1200.32.3608 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1200.32.3604 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1200.32.3605 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1200.32.3606 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1200.32.3601 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.32.3603 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.32.3602 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.32.3609 Boehringer Ingelheim Investigational Site
Taoyuan, Taiwan
Thailand
1200.32.3704 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1200.32.3702 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
1200.32.3703 Boehringer Ingelheim Investigational Site
Khonkaen, Thailand
1200.32.3701 Boehringer Ingelheim Investigational Site
Songkla, Thailand
Ukraine
1200.32.5601 Boehringer Ingelheim Investigational Site
Dnipropetrovks, Ukraine
1200.32.5605 Boehringer Ingelheim Investigational Site
Donetsk, Ukraine
1200.32.5604 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1200.32.5603 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
United Kingdom
1200.32.4808 Boehringer Ingelheim Investigational Site
Exeter, United Kingdom
1200.32.4803 Boehringer Ingelheim Investigational Site
Guildford, United Kingdom
1200.32.4801 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.32.4807 Boehringer Ingelheim Investigational Site
Maidstone, United Kingdom
1200.32.4805 Boehringer Ingelheim Investigational Site
Scunthorpe, United Kingdom
1200.32.4802 Boehringer Ingelheim Investigational Site
Sutton, United Kingdom
1200.32.4806 Boehringer Ingelheim Investigational Site
Truro, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00949650     History of Changes
Other Study ID Numbers: 1200.32, 2008-005615-18
Study First Received: July 29, 2009
Results First Received: August 8, 2013
Last Updated: December 5, 2013
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Australia: Dept of Health and Ageing Therapeutic Goods Admin
Austria: Medicines and Medical Devices Agency
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
Chile: Instituto de Salud Pública de Chile
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
Ireland: Irish Medicines Board
Italy: Ethics Committee
Japan: Pharmaceuticals and Medical Devices Agency
Korea: Food and Drug Administration
Malaysia: Ministry of Health
Peru: Ministry of Health
Philippines: Bureau of Food and Drugs
Romania: National Medicines Agency
Russia: Pharmacological Committee, Ministry of Health
Taiwan: Department of Health
Thailand: Food and Drug Administration
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Cisplatin
Pemetrexed
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014